Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-099-5 | CAS number: 37625-56-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 September to 8 October 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 992
- Report date:
- 1992
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- CAPA 3050
- IUPAC Name:
- CAPA 3050
- Reference substance name:
- ε-Caprolactone, oligomeric reaction products with propylidynetrimethanol
- EC Number:
- 500-099-5
- EC Name:
- ε-Caprolactone, oligomeric reaction products with propylidynetrimethanol
- Cas Number:
- 37625-56-2
- Molecular formula:
- (C6H14O3)x.C6H10O2 (x=0-6)
- IUPAC Name:
- 2-Oxepanone, polymer with 2-ethyl-2-(hydroxymethyl)-1,3-propanediol
- Reference substance name:
- 2-Oxepanone, polymer with 2-ethyl-2-(hydroxymethyl)-1, 3-propanediol
- IUPAC Name:
- 2-Oxepanone, polymer with 2-ethyl-2-(hydroxymethyl)-1, 3-propanediol
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material (as cited in study report): CAPA 3050
- Substance type: Oligomer
- Physical state: Liquid
- Analytical purity: 100%
- Lot/batch No.: WCB000999
- Expiration date of the lot/batch: 23th August 2015
- Stability under test conditions: Stable for the duration of the study
- Storage condition of test material: Ambient
Constituent 1
Constituent 2
Constituent 3
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- The animals were male and female SPF-derived Hsd/Cpb:WU Wistar rats, obtained from Harlan/CPC, The Netherlands. Male rats wereighed 175-200 g, and females weighed 150-175 g, on arrival. The rats were acclimatised for 5 days.The rats were housed in Macrolon cages in groups of 2 or 3. Standard laboratory diet (RHM-TM, Hope Farms, The Netherlands) was provided ad libitum, except for ca. 18.5 hours prior to dosing until 6 hours after dosing. Water was available ad libitum. The animal room was maintained at a temperature of 21-22°C, and a relative humidity of 50-70%. Artifical light was provided for 12 hours per day, and radio sound was provided for 24 hours per day. There were approximately 16 air changes per hour.Individuals were identified by dye markings on the fur.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1.25% tragacanth solution in distilled water
- Details on oral exposure:
- CAPA 305 was suspended in a 1.25% tragacanth solution in distilled water. The final concentration was 0.2 g/ml. Aliquots of the suspension with a volume of 10 ml/kg body weight were taken, equivalent to 2000 mg/kg, and were administered by stomach tube to fasted rats.
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- Five males and five females
- Control animals:
- no
- Details on study design:
- The rats were observed immediately after dosing, and at 1.5, 3, 6 and 26 hours after application and thereafter on each day for 14 days.The rats were weighed on the day before dosing, at the day of dosing prior to dose administration, and at 2, 7 and 14 days after dosing.At the end of the observation period, the rats were sacrificed by ether inhalation and gross necropsy was performed.
- Statistics:
- A statistical analysis was not required.
Results and discussion
- Preliminary study:
- A preliminary study was not reported.
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: No mortality at the limit dose
- Mortality:
- No mortalities occurred during the 14 day observation period.
- Clinical signs:
- other: A slightly hunched posture and gait were observed in 4 out of 5 males and all females between 1.5 and 3 hours after dosing. Signs had completely disappeared by 26 hours after dosing.
- Gross pathology:
- One male rat had a slightly swollen liver. One female showed a dilated uterus, and in another female the lungs were noted to have the appearance of emphysema. No other abnormalities were noted.
- Other findings:
- No other findings reported.
Any other information on results incl. tables
Dilation of the uterus is considered to be a normal physiological process within the oestrus cycle, and was not thought to be related to treatment. The authors suggested that the emphysema could be a consequence of a slight misdosing, or a compound-related effect.
Applicant's summary and conclusion
- Interpretation of results:
- not classified
- Remarks:
- Migrated informationCriteria used for interpretation of results: EU
- Conclusions:
- The 14 -day acute oral LD50 of CAPA 305 in rats was found to be >2000 mg/kg bw
- Executive summary:
The acute oral toxicity of CAPA 3050 was assessed in 5 male and 5 female Wistar rats. A single oral dose of 2000 mg/kg of CAPA 305, suspended in a 1.25% tragacanth solution in distilled water, was administered via gavage. There were no mortalities during the 14 -day observation period. The only clinical signs noted were abnormal gait and posture, all signs had disappeared within 26 hours of dosing. Reduced weight gain (males) or a small body weight loss was noticed from Day 2 to 7 after dosing; normal body weight gains were observed during the second week of the observation period. Autopsy of the rats at the end of the observation period did not reveal macroscopic abnormalities that were considered treatment-related, with the possible exception of lungs with the appearance of emphysema observed in 1 female rat. Acute oral LD50 of CAPA 305 in rats was therefore found to be > 2000 mg/kg bw under the conditions of this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
